Researchers analyzed 24 studies to evaluate the 2023 ACR/EULAR criteria for antiphospholipid syndrome (APS). This analysis compared the new criteria against expert clinical diagnoses and older standards. The results showed that the 2023 criteria have a very high specificity of 0.99, meaning they are highly accurate at identifying who has the condition when the test is positive.
However, the sensitivity of these criteria depends on the specific symptoms a patient shows. While the criteria showed a sensitivity of 0.82 for patients with thrombotic APS, the sensitivity was much lower for patients with obstetric APS, ranging between 0.20 and 0.31. This means the test might miss some cases in certain groups.
Because the results vary based on the patient's specific symptoms, these criteria are intended for classification rather than as a primary tool for clinical diagnosis. Patients with obstetric symptoms may not be identified as easily by these specific criteria. You should talk to your doctor to understand how these findings apply to your specific medical situation.
Common questions
How accurate are the 2023 criteria for identifying antiphospholipid syndrome?
The 2023 ACR/EULAR criteria show a very high specificity of 0.99. This means the criteria are very reliable at correctly identifying patients who have the condition. However, because the sensitivity varies depending on whether a patient has thrombotic or obstetric symptoms, these criteria are primarily used for classification rather than as a standalone tool for clinical diagnosis.
Are these criteria effective for patients with obstetric symptoms?
The study found that sensitivity is much lower for obstetric antiphospholipid syndrome. When looking at specific data, sensitivity for these cases was between 0.20 and 0.31. Because of this lower sensitivity in specific groups, the 2023 criteria may not catch all cases for patients presenting with obstetric symptoms.
How do these results compare to cases involving blood clots?
The 2023 criteria showed a higher sensitivity of 0.82 for patients with thrombotic antiphospholipid syndrome. While this is higher than the results for obstetric cases, the study notes that the criteria are intended for classification. You should consult your doctor to discuss how these specific results relate to your personal health.
